Literature DB >> 1355678

Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.

I Roots1, J Brockmöller, N Drakoulis, R Loddenkemper.   

Abstract

Epidemiological studies suggested a protective effect of certain phenotypes of polymorphic foreign-compound-metabolizing enzymes in some types of cancer. Poor metabolizers (PM) of debrisoquine 4-hydroxylase (cytochrome P-450IID6, CYP2D6) were found to be underrepresented among patients with lung cancer. Recent advances in molecular genetic characterization of CYP2D6, glutathione S-transferase (GST) class Mu, and arylamine N-acetyltransferase enabled genotypical determination of mutant alleles in lung cancer patients. Restriction fragment length polymorphism (RFLP) with a cDNA gene probe of CYP2D6 was analyzed in 79 lung cancer patients who were phenotyped with debrisoquine. Mutant alleles were detected by allele-specific polymerase chain reaction (PCR). In the same individuals, genotype of GST class Mu was analyzed by PCR and correlated with ex vivo activity of glutathione conjugation towards trans-stilbene oxide. RFLP patterns allowed discrimination between the slow and fast genotype of N-acetyltransferase as well as the heterozygotes. Three phenotypical PMs of debrisoquine (3.8%) were confirmed by PCR and RFLP. No PM could be unambiguously recognized only by RFLP patterns. The PMs were characterized by PCR and RFLP as carriers of the 29B/29B (n = 1), 29A/29B (n = 1), and 29A/44 (n = 1) mutant alleles. Higher debrisoquine hydroxylase activities were found in the homozygous EMs, who possess two active genes, as compared to heterozygous EMs, who have only one active gene. The patients with phenotypically impaired GST Mu activity were confirmed as such by PCR. A complete correspondence between phenotyping of N-acetyltransferase (with caffeine) and genotyping was found. The new genetic techniques proved to be powerful tools for molecular-epidemiological studies aimed at establishing host factors of cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355678     DOI: 10.1007/bf00184667

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  59 in total

1.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

2.  Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.

Authors:  W E Evans; M V Relling
Journal:  Mol Pharmacol       Date:  1990-05       Impact factor: 4.436

3.  Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.

Authors:  J Seidegård; W R Vorachek; R W Pero; W R Pearson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

4.  Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

Authors:  M Eichelbaum; M P Baur; H J Dengler; B O Osikowska-Evers; G Tieves; C Zekorn; C Rittner
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

5.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

6.  Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung.

Authors:  A Weston; J C Willey; R Modali; H Sugimura; E M McDowell; J Resau; B Light; A Haugen; D L Mann; B F Trump
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

Review 7.  Genetic predisposition to lung cancer.

Authors:  M R Law
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

8.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

9.  Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study.

Authors:  J Seidegård; R W Pero; M M Markowitz; G Roush; D G Miller; E J Beattie
Journal:  Carcinogenesis       Date:  1990-01       Impact factor: 4.944

10.  Lung cancer and the debrisoquine metabolic phenotype.

Authors:  N E Caporaso; M A Tucker; R N Hoover; R B Hayes; L W Pickle; H J Issaq; G M Muschik; L Green-Gallo; D Buivys; S Aisner
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

View more
  6 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

2.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

3.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

Authors:  P M Christensen; P C Gøtzsche; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region.

Authors:  N Drakoulis; I Cascorbi; J Brockmöller; C R Gross; I Roots
Journal:  Clin Investig       Date:  1994-02

Review 5.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

Review 6.  Genetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-Analysis.

Authors:  Su Kang Kim; Sang Wook Kang; Joo-Ho Chung; Hae Jeong Park; Kyu Bong Cho; Min-Su Park
Journal:  Int J Mol Sci       Date:  2015-08-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.